Baricitinib for the treatment of COVID-19
Austrian Institute for Health Technology Assessment (AIHTA)
Record ID 32018001197
English
Authors' objectives:
The aim of this EUnetHTA Rolling Collaborative Review is
to inform health policy at the national/regional and at the European level at an early stage in the life-cycle of therapies which interventions are currently undergoing clinical trials,
to monitor (ongoing studies and their results) permanently - in the format of a Living Document - potential therapies against covid-19,
to present comparative data on effectiveness and safety of potential therapies and to support preparations for an evidence-based purchasing of regional/ national health politicians, if necessary.
To avoid redundancies and duplication, the EUnetHTA Rolling Collaborative Review will reuse sources from international initiatives to collect information and data on Covid-19 treatments.
Details
Project Status:
Completed
URL for project:
https://eunethta.eu/rcr18/
Year Published:
2021
URL for published report:
https://eunethta.eu/rcr18/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- COVID-19
- SARS-CoV-2
- Coronavirus Infections
- Antiviral Agents
- Azetidines
- Drug Therapy
- Janus Kinase Inhibitors
- Purines
- Pyrazoles
- Sulfonamides
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.